Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe – Arrowhead Pharmaceuticals, Inc.
Posted by admin
on Friday, April 24, 2026 at 10:46 am — No Comments | Leave a Comment